Login

If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

News

Home > News

Please scroll down to find news and features relating to the NOVELTY study as we embark on this journey of discovery, or click on the image to the right for extra news for investigators and AstraZeneca Medical employees.

Extra news for investigators and AstraZeneca Medical employees

Read More

News

9th September, 2023

NOVELTY at ERS 2023

Read More

11th June, 2023

Burden of uncontrolled severe asthma manuscript published

Read More

23rd May, 2023

NOVELTY cluster analysis manuscript published

Read More

8th April, 2023

CAAT psychometric validation manuscript published

We are pleased to announce that ‘Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD’ has been published in Respiratory Research.
Read More

3rd April, 2023

ADPro substudy methodology manuscript published

We are pleased to announce that ‘Functional imaging in asthma and COPD: design of the NOVELTY ADPro substudy’ has been published in ERJ Open Research.
Read More

14th November, 2022

Deep learning approach for lung cavity estimation manuscript published

Now published in the Journal of Magnetic Resonance Imaging: Deep learning approach for lung cavity estimation by 129Xe MRI and proton MRI.
Read More

14th November, 2022

GOLD 2023 cites NOVELTY article on treatable traits

The newly published GOLD 2023 report cites the ‘Treatable traits in the NOVELTY study’ article.
Read More

6th September, 2022

NOVELTY scientific congress presence in 2022

Several NOVELTY abstracts have been presented at 2022 events.
Read More

21st July, 2022

NOVELTY treatable traits manuscript published

Now published in Respirology: Treatable traits in the NOVELTY study.
Read More

19th June, 2022

NOVELTY frequent productive cough manuscript published

Now published in Respiratory Medicine: Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study, with accompanying video summary.
Read More

7th May, 2022

NOVELTY mild asthma burden manuscript published

Now published in Respiratory Medicine: the burden of mild asthma in patients from the NOVELTY study.
Read More

8th December, 2021

NOVELTY 2-year extension study announced

We are pleased to announce that an extension period is planned for the NOVELTY study, in which a subset of approximately 3,000 patients will continue to be followed for up to an additional 2 years following completion of the main 3-year study.
Read More

6th July, 2021

Validation of the CAAT in NOVELTY ePoster Presented at ATS 2021

The validation of the Chronic Airways Assessment Test (CAAT) - ePoster presented at the ATS International Conference 2021.
Read More
19 PARTICIPATING COUNTRIESa
~12,000 ENROLLED PATIENTSa
84% OF PATIENTS HAVE SPIROMETRY DATAb

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study